Top

Published in:

01-03-2016 | AdisInsight Report

Elotuzumab: First Global Approval

Author: Anthony Markham

Published in: Drugs | Issue 3/2016

Abstract

Elotuzumab (Empliciti™) is a humanised IgG1 monoclonal antibody developed by Bristol-Myers Squibb (BMS) and AbbVie that has been approved as combination therapy with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in the US. Elotuzumab binds to the cell surface receptor signalling lymphocytic activation molecule F7 (SLAMF7), which is selectively expressed on myeloma cells and natural killer cells, leading to antibody-dependent cellular cytotoxicity and direct natural killer cell activation. In a phase III clinical trial, addition of elotuzumab to lenalidomide and dexamethasone therapy in patients with relapsed/refractory multiple myeloma was associated with a significant improvement in progression-free survival and overall response rate. This article summarizes the milestones in the development of elotuzumab leading to this first approval for relapsed/refractory multiple myeloma.

Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–37.PubMedCentralCrossRefPubMed

Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–84.PubMedCentralCrossRefPubMed

US Food and Drug Administration. Elotuzumab [media release]. 30 Nov 2015. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474719.htm.

Bristol-Myers Squibb Company. Empliciti^TM (elotuzumab) for injection, for intravenous use: US prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761035s000lbl.pdf. Accessed 1 Dec 2015.

Bristol-Myers Squibb. European Medicines Agency validates and grants accelerated assessment of marketing authorization application for Empliciti (elotuzumab) for the treatment of multiple myeloma in patients who have received one or more prior therapies [media release]. 27 Jul 2015.

Bristol-Myers Squibb Company. Bristol-Myers Squibb and PDL BioPharma enter global alliance to develop novel treatment for multiple myeloma [media release]. 19 Aug 2008.

Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. Biomed Res Int. 2015;2015:341430.PubMedCentralPubMed

Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–9.PubMedCentralCrossRefPubMed

van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–24.PubMedCentralCrossRefPubMed

10.

Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab in combination with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase 1b study. Clin Lymphoma Myeloma Leuk. 2015. doi:10.1016/j.clml.2015.12.007.PubMed

11.

Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.CrossRefPubMed

12.

Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–27.CrossRefPubMed

13.

Jakubowiak A, Offidani M, Pegourie B, et al. A randomized, open-label, phase 2 study of bortezomib and dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma [abstract no. S103]. Haematologica. 2015;100(Suppl 1):2.

14.

Jakubowiak AJ, Offidani M, Pegourie B, et al. A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) [abstract no. 8573]. J Clin Oncol. 2015;33(15 Suppl 1).

15.

Mateos MV, Granell M, Rocafiguera AO, et al. A phase II single-arm safety study of elotuzumab in combination with thalidomide and low dose dexamethasone in patients with relapsed and/or refractory multiple myeloma [abstract no. P959]. Haematologica. 2014;99(Suppl 1).

16.

Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–5.CrossRefPubMed

17.

Usmani SZ, Sexton R, Ailawadhi S, et al. SWOG 1211: initial report on phase I trial of RVD-elotuzumab for newly diagnosed high risk multiple myeloma (HRMM) [abstract no. 4762 plus poster]. In: 56th annual meeting and exposition of the American Society of Hematology; 2014; San Francisco, CA.

18.

Usmani SZ, Sexton R, Ailawadhi S, et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015;5:e334.PubMedCentralCrossRefPubMed

19.

Usmani SZ, Hoering A, Sexton R, et al. SWOG 1211: a randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM) [abstract no. TPS8624]. J Clin Oncol. 2014;32(15 Suppl 1).

20.

Dimopoulos M, Facon T, Richardson P, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006) [abstract no. TPS8113]. J Clin Oncol. 2012;30(15 Suppl).

Title: Elotuzumab: First Global Approval
Author: Anthony Markham
Publication date: 01-03-2016
Publisher: Springer International Publishing
Published in: Drugs / Issue 3/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-016-0540-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Elotuzumab: First Global Approval

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Erratum to: Cariprazine: First Global Approval

Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus

Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?

Ixazomib: First Global Approval

Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy

Selexipag: First Global Approval